AbbVie (ABBV) Common Equity (2012 - 2026)

AbbVie has disclosed Common Equity across 15 years of filings, most recently posting -$6.6 billion for Q1 2026.

• In Q1 2026, Common Equity fell 552.26% year-over-year to -$6.6 billion; the TTM figure through Mar 2026 stood at -$6.6 billion (down 552.26% YoY), while the FY2025 annual figure was -$3.2 billion, down 195.96% from the prior year.
• Common Equity fell to -$6.6 billion in Q1 2026, from -$3.2 billion in the prior quarter.
• Over the last five years, Common Equity for ABBV reached as high as $17.3 billion in Q4 2022 and fell as low as -$6.6 billion in Q1 2026.
• The 5-year median for Common Equity is $8.0 billion (2024), against an average of $7.4 billion.
• Annual changes were most pronounced in 2022 — Common Equity gained 18.79% — and 2026, when it plunged 552.26%.
• A 5-year view of Common Equity shows it stood at $17.3 billion in 2022, then sank by 39.86% to $10.4 billion in 2023, then slumped by 67.64% to $3.4 billion in 2024, then plunged by 195.96% to -$3.2 billion in 2025, then plunged by 104.83% to -$6.6 billion in 2026.
• According to Business Quant data, Common Equity over the past three periods registered -$6.6 billion, -$3.2 billion, and -$2.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.